ANCN vs. PXMD, PTPI, SNGX, KZIA, DRUG, SNPX, ENSC, GTBP, CPHI, and SONN
Should you be buying Anchiano Therapeutics stock or one of its competitors? The main competitors of Anchiano Therapeutics include PaxMedica (PXMD), Petros Pharmaceuticals (PTPI), Soligenix (SNGX), Kazia Therapeutics (KZIA), Bright Minds Biosciences (DRUG), Synaptogenix (SNPX), Ensysce Biosciences (ENSC), GT Biopharma (GTBP), China Pharma (CPHI), and Sonnet BioTherapeutics (SONN). These companies are all part of the "medical" sector.
Anchiano Therapeutics (NASDAQ:ANCN) and PaxMedica (NASDAQ:PXMD) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, dividends, community ranking, analyst recommendations, earnings, risk, valuation, institutional ownership and media sentiment.
PaxMedica has a consensus target price of $3.00, suggesting a potential upside of 326.02%. Given PaxMedica's higher probable upside, analysts clearly believe PaxMedica is more favorable than Anchiano Therapeutics.
Anchiano Therapeutics has a beta of 0.93, suggesting that its share price is 7% less volatile than the S&P 500. Comparatively, PaxMedica has a beta of 0.61, suggesting that its share price is 39% less volatile than the S&P 500.
Anchiano Therapeutics received 57 more outperform votes than PaxMedica when rated by MarketBeat users. However, 100.00% of users gave PaxMedica an outperform vote while only 65.91% of users gave Anchiano Therapeutics an outperform vote.
9.1% of Anchiano Therapeutics shares are held by institutional investors. Comparatively, 4.9% of PaxMedica shares are held by institutional investors. 6.9% of Anchiano Therapeutics shares are held by company insiders. Comparatively, 57.9% of PaxMedica shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
In the previous week, PaxMedica had 4 more articles in the media than Anchiano Therapeutics. MarketBeat recorded 4 mentions for PaxMedica and 0 mentions for Anchiano Therapeutics. Anchiano Therapeutics' average media sentiment score of 0.00 beat PaxMedica's score of -0.48 indicating that Anchiano Therapeutics is being referred to more favorably in the media.
Anchiano Therapeutics' return on equity of 36.08% beat PaxMedica's return on equity.
Anchiano Therapeutics is trading at a lower price-to-earnings ratio than PaxMedica, indicating that it is currently the more affordable of the two stocks.
Summary
Anchiano Therapeutics beats PaxMedica on 8 of the 14 factors compared between the two stocks.
Get Anchiano Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ANCN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ANCN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Anchiano Therapeutics Competitors List
Related Companies and Tools
